Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...

Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.

(UroToday.com) The 2026 SESAUA annual meeting featured the Gee-Dineen lecture series and a presentation by Dr. Andrew Harris discussing the state of the Urology workforce. Dr. Harris started his ...

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical trial updates session and presentation by Dr. Désirée Deandreis discussing the PEACE-6 PR trial. Recently, prostate cancer is ...

(UroToday.com) The 2026 ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Andrea Apolo discussing an updated subgroup analysis of the phase 3 CheckMate-9ER trial assessing ...

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Andrea Malgeri presented a reconstructed individual ...

(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Oliver Sartor discussing AcTFirst, a phase 3 trial of 225 Ac-PSMA-617 + ...

ASCO GU 2023 Press Releases Clinical Data Presented at ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Cabometyx® in Combination with ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Christian Engesser discussing ...